Charmy Twala

Mr. Charmy Twala

School of Agriculture and Life Sciences, Department of Life and Consumer Sciences, University of South Africa, Science Campus, Florida Park
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
RSRazia Sultana
Razia Sultana
Asghar AliAsghar Ali
Asghar Ali
CTCharmy Twala
Charmy Twala
RMRabiya Mehandi
Rabiya Mehandi
MRManish Rana
Manish Rana
RARahisuddin
Rahisuddin
We have synthesized the pyrazole-bearing Schiff base derivatives (5a–5e) and (6a–6h) then the structural confirmation was supported by various spectral analyses. The antibacterial activity of all analogs was screened against bacterial strains Staphylococcus aureus, Bacillus subtilis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumonieae and Pseudomonas aeruginosa. In comparison to the reference drug ciprofloxacin, the lead analogs 5c and 6c showed potent activity, with MIC values of 64 µg/mL against E. coli and B. subtilis. Compound 5c showed a moderate effect with a MIC value of 128 µg/mL against B. subtilis, P. aeruginosa and K. pneumonieae, while compound 6c was against E. coli and P. aeruginosa. Furthermore, the compounds 5c and 6c displayed groove binding mode towards CT-DNA by absorption, emission, competitive fluorescence studies using EtBr, CD and time-resolved fluorescence studies. Thermodynamic parameters of analogs 5c and 6c with CT-DNA were also calculated at 298, 303 and 308K temperatures by UV–visible spectroscopy. The molecular docking studies give the docking score for all compounds with PDB codes: 1BNA and 2XCT. The MD simulation study of analogs 5c and 6c was also carried out. The pharmacokinetic and ADME properties were calculated for all of the synthesized analogs (5a–5e) and (6a–6h). Communicated by Ramaswamy H. Sarma

14 December 2023 in Journal of Organometallic Chemistry
Verified
Journal Article
Closed access
RMRabiya Mehandi
Rabiya Mehandi
CTCharmy Twala
Charmy Twala
Asghar AliAsghar Ali
Asghar Ali
SASaiema Ahmedi
Saiema Ahmedi
MRManish Rana
Manish Rana
NNNahid Nishat
Nahid Nishat

6 November 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CTCharmy Twala
Charmy Twala
Penny P. GovenderPenny P. Govender
Penny P. Govender
KGKrishna Kuben Govender
Krishna Kuben Govender
Poly (ADP-ribose) polymerase 1 (PARP1) is an important enzyme that plays a central role in the DNA damage response, facilitating repair of single-stranded DNA breaks via the base excision repair (BER) pathway and thus genomic integrity. Its therapeutic relevance is compounded in breast cancer, particularly in BRCA1 or BRCA2 mutant cancers, where compromised homologous recombination repair (HRR) leaves a synthetic lethal dependency on PARP1-mediated repair. This review comprehensively discusses the recent advances in computational chemistry for the discovery of PARP1 inhibitors, focusing on their application in breast cancer therapy. Techniques such as molecular docking, molecular dynamics (MD) simulations, quantitative structure–activity relationship (QSAR) modeling, density functional theory (DFT), time-dependent DFT (TD-DFT), and machine learning (ML)-aided virtual screening have revolutionized the discovery of inhibitors. Some of the most prominent examples are Olaparib (IC50 = 5 nM), Rucaparib (IC50 = 7 nM), and Talazoparib (IC50 = 1 nM), which were optimized with docking scores between −9.0 to −9.3 kcal/mol and validated by in vitro and in vivo assays, achieving 60–80% inhibition of tumor growth in BRCA-mutated models and achieving up to 21-month improvement in progression-free survival in clinical trials of BRCA-mutated breast and ovarian cancer patients. These strategies enable site-specific hopping into the PARP1 nicotinamide-binding pocket to enhance inhibitor affinity and specificity and reduce off-target activity. Employing computation and experimental verification in a hybrid strategy have brought next-generation inhibitors to the clinic with accelerated development, higher efficacy, and personalized treatment for breast cancer patients. Future approaches, including AI-aided generative models and multi-omics integration, have the promise to further refine inhibitor design, paving the way for precision oncology.

14 January 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
CTCharmy Twala
Charmy Twala
SMSibusiso Tebogo Malindisa
Sibusiso Tebogo Malindisa
CMChamone Munnik
Chamone Munnik
SSSelisha Ann Sooklal
Selisha Ann Sooklal
Monde NtwasaMonde Ntwasa
Monde Ntwasa
Background: Ezetimibe is used to treat cardiovascular disease as it blocks the sterol transporter Niemann-Pick C1-Like 1 (NPC1CL1) protein. However, recent evidence indicates that Ezetimibe inhibits several cancers indirectly by reducing circulating cholesterol or via specific signalling pathways. Methods and Results: Our in silico studies indicate that Ezetimibe binds to the Tp53 binding domain in Mdm2, forming a more thermodynamically stable complex than nutlin3a. Furthermore, a docking study of the newly developed inhibitors—RG7388 and RG7112—was conducted. This further showed lower binding energies of −6.337 kcal/mol and −6.222 kcal/mol, respectively, when compared to the −7.919 kcal/mol exhibited by Ezetimibe. We show that Ezetimibe inhibits the growth of several cancer cell lines at concentrations that are not toxic to a normal cell line. Conclusions: Thus, Ezetimibe is probably active against cancers that overexpress Mdm2. Moreover, inhibitors of RBBP6 may be combined with Ezetimibe for effective anticancer activity. Due to poor oral bioavailability, Ezetimibe must be administered parenterally for cancer treatment.

10 June 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CTCharmy Twala
Charmy Twala
Penny P. GovenderPenny P. Govender
Penny P. Govender
EMEphraim Felix Marondedze
Ephraim Felix Marondedze
KGKrishna Kuben Govender
Krishna Kuben Govender
Background/Objectives: Poly (ADP-ribose) polymerase (PARP1) has emerged as a promising therapeutic target in human breast cancer particularly in BRCA1/2 mutation carriers where a synthetic lethal interaction leads to massive tumor cell death upon specific inhibitors’ administration. Current clinically approved PARP inhibitors (Talazoparib and Olaparib) show outstanding therapeutic capabilities but suffer from severe side effects. Most importantly, some of them can cause life-threatening cardiotoxicity through hERG off-target effects. Here, we performed an extensive study to identify lead compounds with improved binding modes and favorable predicted pharmacokinetics using an integrated computational strategy. Methods: An artificial intelligence-driven drug design (AIDDISON™ v2023) workflow was employed to search ultra-large chemical space libraries for active compounds, which were then optimized via computer-aided methods to form a PARP-Tailored Database (PTD). This database was then analyzed through a virtual screening workflow, molecular docking studies, molecular dynamics (MD) simulations, MM/GBSA binding free energy calculations, DFT analysis and ADME/Tox predictions using the Schrödinger suite (v2023-2), MobaXterm v25.2, Gaussian 16.0, ProTox-3 and Pred-hERG v5.0 respectively. Results: Three compounds (1a–1c) were identified as promising candidates. Among them 1a appeared to be the most active compound with a favorable docking score (−9.488 kcal/mol) that is not only higher than 1b and 1c but also higher than that of Talazoparib (−6.778 kcal/mol). MD simulations of 1a–1c in the active site revealed an average RMSD of ~2.5–3.6 Å which is better compared to the parent Talazoparib (5.6 Å). Interestingly, on the 250 ns extended MD study, 1a exhibited a slightly reduced RMSD between 2.4 and 3.2 Å, whereas Talazoparib retained higher fluctuations of ~5 Å to 6 Å. MM/GBSA binding energy analysis indicated 1a to have better predicted binding affinity (−67.820 kcal/mol), which is also better than Talazoparib (−63.734 kcal/mol). DFT calculations showed good electronic properties and in silico ADMET studies also indicated 1a to have good drug-likeness and lower predicted hepatotoxicity and cardiotoxicity risk. Conclusions: These findings identify compound 1a as a promising lead, while compounds 1b and 1c remain viable candidates for further optimization. However, experimental validation is critical to confirm the predicted biological activity and safety profiles.

14 March 2024 in Research Square
Verified
Preprint
Open access
PDF file
CTCharmy Twala
Charmy Twala
BRBonnie Russell
Bonnie Russell
SMSibusiso Malindisa
Sibusiso Malindisa
CMChamone Munnik
Chamone Munnik
SSSelisha Sooklal
Selisha Sooklal
MNMonde Ntwasa
Monde Ntwasa
Ezetimibe is used to treat cardiovascular disease as it blocks the sterol transporter Niemann-Pick C1-Like 1 (NPC1CL1) protein. However, recent evidence indicates that ezetimibe inhibits several cancers, indirectly by reducing circulating cholesterol or via specific signalling pathways. Our in-silico studies indicate that ezetimibe binds to the Tp53 binding domain in Mdm2, forming a more thermodynamically stable complex than nutlin3a. Moreover, we show that Tp53 functions in complex with the Retinoblastoma Binding Protein 6 (RBBP6), another negative regulator of p53, and Mdm2. RBBP6 is dysregulated in many cancers, and various studies and may be a prognostic biomarker for certain cancers. We show that ezetimibe inhibits the growth of several cancer cell lines at concentrations that are not toxic to a normal cell line. Thus ezetimibe is probably active against cancers that overexpress Mdm2. Moreover, inhibitors of RBBP6 may be combined with ezetimibe for effective anticancer activity. Due to poor oral bioavailability ezetimibe must be administered parenterally for cancer treatment.